These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. [Radioimmunotherapy for non-Hodgkin lymphoma: historical development and current status]. Emmanouilides C Rev Esp Med Nucl; 2006; 25(1):42-54. PubMed ID: 16540013 [TBL] [Abstract][Full Text] [Related]
11. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Gordon LI; Witzig T; Molina A; Czuczman M; Emmanouilides C; Joyce R; Vo K; Theuer C; Pohlman B; Bartlett N; Wiseman G; Darif M; White C Clin Lymphoma; 2004 Sep; 5(2):98-101. PubMed ID: 15453924 [TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy for B-cell non-hodgkin lymphomas. Tomblyn M Cancer Control; 2012 Jul; 19(3):196-203. PubMed ID: 22710895 [TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy and Autologous Stem-Cell Transplantation in the Treatment of B-Cell Non-Hodgkin Lymphoma. Shimoni A; Zwas ST Semin Nucl Med; 2016 Mar; 46(2):119-25. PubMed ID: 26897716 [TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies. Kawashima H ScientificWorldJournal; 2014; 2014():492061. PubMed ID: 25379535 [TBL] [Abstract][Full Text] [Related]
15. Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma. Weigert O; Illidge T; Hiddemann W; Dreyling M Cancer; 2006 Aug; 107(4):686-95. PubMed ID: 16826593 [TBL] [Abstract][Full Text] [Related]
16. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300 [TBL] [Abstract][Full Text] [Related]
17. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Wiseman GA; White CA; Stabin M; Dunn WL; Erwin W; Dahlbom M; Raubitschek A; Karvelis K; Schultheiss T; Witzig TE; Belanger R; Spies S; Silverman DH; Berlfein JR; Ding E; Grillo-López AJ Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488 [TBL] [Abstract][Full Text] [Related]
18. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209 [TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. Juweid ME J Nucl Med; 2002 Nov; 43(11):1507-29. PubMed ID: 12411555 [TBL] [Abstract][Full Text] [Related]
20. Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates. Leonard JP Hematology Am Soc Hematol Educ Program; 2005; ():335-9. PubMed ID: 16304400 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]